Topics

Articles

An exploration into how flawed incentives and contractual loopholes between manufacturers and pharmacy benefit managers played their part.

Popping the Gross-to-Net Bubble, Part IV: Extreme Examples of Who Grew the Bubble

How practical is this form of pricing in the pharma setting?

Reviewing the Most-Favored Nation Model

Videos

In the final part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, illustrates how data-driven insights can support PBMs and healthcare leaders in negotiating fairer drug prices?

Using Data to Influence Drug Pricing Policy 

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Bridging the Gap Between Strategy and Practice in IDN Partnerships

A cross-sectional study explores how full-benefit dual-eligible beneficiaries differ across MA plans with differing levels of Medicaid coordination and integration.

The Variation in Dual-Eligible Beneficiary Characteristics across Medicare Advantage Plan Types

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’

BioNTech, BMS to Co-Design and Co-Commercialize New Antibody Candidate for Various Types of Tumors

Podcasts

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

How Recent Executive Orders Impact the Drug Pricing Landscape

An NEJM study explores how this loss—following Medicaid disenrollment—affects beneficiaries.

How the Loss of Subsidized Drug Coverage Could Impact Mortality 

Andrew Witty resigns due to personal reasons, as Stephen Hemsley, chairman and former chief executive, will assume the position.

UnitedHealth Group CEO Departs

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

Market Access